← Search & browse all drugs

morphine, combinations

N02AA51

Forms & Strengths

Oral capsules, extended-release (morphine/naltrexone combinations)
Oral tablets, extended-release
Injectable solutions (morphine sulfate with various adjuvants)

Adult Dosing

Pain, chronic severe: Titrated individually based on previous analgesic history, opioid tolerance, and patient response.
Conversion from other opioids: Utilize standard equianalgesic conversion tables, reducing dose by 25-50% to account for incomplete cross-tolerance.

Pediatric Dosing

Safety and efficacy in pediatric patients not established for combination formulations.
Use restricted primarily to single-entity morphine formulations under specialist supervision in inpatient settings.

Indications

Management of chronic, severe pain requiring continuous, around-the-clock opioid analgesia for an extended period.
Pain unresponsive to lesser analgesic modalities.

Mechanism of Action

Agonist at mu, kappa, and delta opioid receptors in the central nervous system and periphery, altering pain perception and response.
Formulations with naltrexone or other antagonists are designed to deter misuse or abuse via the oral or intravenous route while maintaining analgesia.

Contraindications

Significant respiratory depression
Acute or severe bronchial asthma in an unmonitored setting or absence of resuscitative equipment
Known or suspected gastrointestinal obstruction, including paralytic ileus
Hypersensitivity to morphine or any component of the formulation

Adverse Reactions

Respiratory depression and arrest
Central nervous system depression (somnolence, dizziness, sedation)
Constipation, nausea, vomiting
Hypotension, orthostatic hypotension
Physical dependence, tolerance, and opioid use disorder

Drug Interactions

Central nervous system depressants (alcohol, benzodiazepines, general anesthetics): profound sedation, respiratory depression, coma, and death.
CYP3A4 and UGT inhibitors/inducers may alter the metabolism of associated agents.
Serotonergic drugs (SSRIs, SNRIs, MAOIs): increased risk of serotonin syndrome.
Mixed agonist-antagonist/partial agonist opioid analgesics: may precipitate withdrawal symptoms or reduce analgesic effect.

Curated Content: Needs Vetting Before Put to Clinical Use